BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis

Schizophrenia Research

Volumn 152, Issue 2-3, 2014, Pages 365-372

  Miura, Itaru ^a,b   Zhang, Jian Ping ^a,c,d   Nitta, Masahiro ^a,e   Lencz, Todd ^a,c,d,f   Kane, John M ^a,c,d,f   Malhotra, Anil K ^a,c,d,f   Yabe, Hirooki ^b   Correll, Christoph U ^a,c,d,f  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

AIMS; BDNF; Genotype; Race; Schizophrenia; Tardive dyskinesia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; NEUROLEPTIC AGENT; VALINE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AGE; ALLELE; ASIAN; BDNF GENE; CAUCASIAN; DISEASE ASSOCIATION; DISEASE SEVERITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEX RATIO; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

AIMS; BDNF; GENOTYPE; RACE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DATABASES, BIBLIOGRAPHIC; FEMALE; GENOTYPE; HUMANS; MALE; METHIONINE; MIDDLE AGED; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; VALINE;

EID: 84892863900     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.12.011     Document Type: Review

References (56)

1. Andreasen N.C., Liu D., Ziebell S., Vora A., Ho B.C. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am. J. Psychiatry 2013, 170(6):609-615.
2. Andreassen O.A., Jørgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Prog. Neurobiol. 2000, 61(5):525-541.
3. Angelucci F., Brenè S., Mathé A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10(4):345-352.
4. Ascher-Svanum H., Zhu B., Faries D., Peng X., Kinon B.J., Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J. Clin. Psychiatry 2008, 69(10):1580-1588.
5. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr. Res. 2006, 83(2-3):185-192.
6. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol. Psychiatry 2008, 13(5):544-556.
7. Bakker P.R., Bakker E., Amin N., van Duijn C.M., van Os J., van Harten P.N. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One 2012, 7(5):e36561.
8. Comprehensive Meta-analysis. 2 2005, Biostat, New Jersey. M. Borenstein, L. Hedges, J. Higgins, H. Rothstein (Eds.).
9. Browne S., Roe M., Lane A., Gervin M., Morris M., Kinsella A., Larkin C., Callaghan E.O. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996, 94(2):118-124.
10. Cho C.H., Lee H.J. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:207-213.
11. Chong S.A., Tan E.C., Tan C.H., Mythily, Chan Y.H. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 116B(1):51-54.
12. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 2008, 21(2):151-156.
13. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 2004, 161(3):414-425.
14. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269.
15. Glazer W.M., Morgenstern H., Doucette J.T. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J. Clin. Psychiatry 1993, 54(4):133-139.
16. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68(2):128-137.
17. Hori H., Ohmori O., Shinkai T., Kojima H., Nakamura J. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. 2001, 105(8):774-778.
18. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
19. Hung H.C., Lee E.H. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+toxicity: role of BDNF gene expression. Brain Res. Mol. Brain Res. 1996, 41(1-2):14-26.
20. Jeste D.V., Lacro J.P., Palmer B., Rockwell E., Harris M.J., Caligiuri M.P. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am. J. Psychiatry 1999, 156(2):309-311.
21. Kane J.M., Woerner M., Weinhold P., Wegner J., Kinon B., Borenstein M. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol. Bull. 1984, 20(3):387-389.
22. Kang S.G., Choi J.E., An H., Lim S.W., Lee H.J., Han C., Kim Y.K., Kim S.H., Cho S.N., Lee M.S., Joe S.H., Jung I.K., Kim L. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(6):1545-1548.
23. Knüsel B., Gao H., Okazaki T., Yoshida T., Mori N., Hefti F., Kaplan D.R. Ligand-induced down-regulation of Trk messenger RNA, protein and tyrosine phosphorylation in rat cortical neurons. Neuroscience 1997, 78(3):851-862.
24. Lee J.G., Shin B.S., Lee Y.C., Park S.W., Kim Y.H. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial. Psychiatry Clin. Neurosci. 2007, 61(5):509-514.
25. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M., HGDH Study Group Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62(4):361-370.
26. Liou Y.J., Liao D.L., Chen J.Y., Wang Y.C., Lin C.C., Bai Y.M., Yu S.C., Lin M.W., Lai I.C. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med. 2004, 5(3):243-251.
27. Liou Y.J., Lai I.C., Liao D.L., Chen J.Y., Lin C.C., Lin C.Y., Chen C.M., Bai Y.M., Chen T.T., Wang Y.C. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr. Res. 2006, 86(1-3):323-325.
28. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17(1):47-62.
29. Marsálek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000, 33(Suppl. 1):14-33.
30. Naoe Y., Shinkai T., Hori H., Sakata S., Fukunaka Y., Utsunomiya K., Shimizu K., Matsumoto C., Ohmori O., Nakamura J. No association between the brain-derived neurotrophic factor (BDNF) gene polymorphism (val66Met) and tardive dyskinesia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B(7):803.
31. Nishio T., Furukawa S., Akiguchi I., Sunohara N. Medial nigral dopamine neurons have rich neurotrophin support in humans. Neuroreport 1998, 9(12):2847-2851.
32. Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 2013, 14(1):7-23.
33. Park S.W., Lee J.G., Kong B.G., Lee S.J., Lee C.H., Kim J.I., Kim Y.H. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin. Neurosci. 2009, 63(4):433-439.
34. Petryshen T.L., Sabeti P.C., Aldinger K.A., Fry B., Fan J.B., Schaffner S.F., Waggoner S.G., Tahl A.R., Sklar P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 2010, 15(8):810-815.
35. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer-Lindenberg A., Weinberger D.R. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J. Neurosci. 2004, 24(45):10099-10102.
36. Pillai A., Terry A.V., Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 2006, 82(1):95-106.
37. Saltz B.L., Woerner M.G., Kane J.M., Lieberman J.A., Alvir J.M., Bergmann K.J., Blank K., Koblenzer J., Kahaner K. Prospective study of tardive dyskinesia incidence in the elderly. J. Am. Med. Assoc. 1991, 266(17):2402-2406.
38. Schooler N.R., Kane J.M. Research diagnosis for tardive dyskinesia. Arch. Gen. Psychiatry 1982, 39(4):486-487.
39. Segman R.H., Goltser T., Heresco-Levy U., Finkel B., Shalem R., Schlafman M., Yakir A., Greenberg D., Strous R., Lerner A., Shelevoy A., Lerer B. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J. 2003, 3(5):277-283.
40. Shinkai T., Müller D.J., De Luca V., Shaikh S., Matsumoto C., Hwang R., King N., Trakalo J., Potapova N., Zai G., Hori H., Ohmori O., Meltzer H.Y., Nakamura J., Kennedy J.L. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res. 2006, 141(2):123-128.
41. Tan Y.L., Zhou D.F., Zhang X.Y. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 2005, 74(2-3):263-270.
42. Tarsy D., Baldessarini R.J. The pathophysiologic basis of tardive dyskinesia. Biol. Psychiatry 1977, 12(3):431-450.
43. Tsai H.T., North K.E., West S.L., Poole C. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B(1):57-66.
44. Tsapakis E., Williams B., Scully P., Quinn J., Wright P., Smith S., Daly A., Gill M., Waddington J., Aitchison K. Association study of the BDNF Val66Met polymorphism with tardive dyskinesia. Schizophr. Res. 2006, 81:196-197. (Suppl.).
45. Tsapakis E.M., Scully P., Quinn J., Wright P., Smith S., Daly A., Waddington J., Aitchison K. A brain-derived neurotrophic factor polymorphism in Caucasians with tardive dyskinesia and Parkinson's disease. Schizophr. Bull. 2007, 33(2):507.
46. Wang Y., Wang J.D., Wu H.R., Zhang B.S., Fang H., Ma Q.M., Liu H., Chen, da C., Xiu M.H., Hail C.N., Kosten T.R., Zhang X.Y. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is not associated with risk for schizophrenia and tardive dyskinesia in Han Chinese population. Schizophr. Res. 2010, 120(1-3):240-242.
47. Xu M.Q., St Clair D., Feng G.Y., Lin Z.G., He G., Li X., He L. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet. Genomics 2008, 18(6):449-457.
48. Xu M.Q., Li S., Xing Q.H., Gao R., Feng G.Y., Lin Z.G., StClair D., He L. Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur. J. Hum. Genet. 2010, 18(6):707-712.
49. Yang Y.Q., Sun S., Yu Y.Q., Li W.J., Zhang X., Xiu M.H., Chen, da C., De Yang F., Liu H., Li C., Kosten T.R., Zhang X.Y. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neurosci. Lett. 2011, 502(1):37-40.
50. Yassa R., Jeste D.V. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull. 1992, 18(4):701-715.
51. Zai C.C., Hwang R.W., De Luca V., Müller D.J., King N., Zai G.C., Remington G., Meltzer H.Y., Lieberman J.A., Potkin S.G., Kennedy J.L. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int. J. Neuropsychopharmacol. 2007, 10(5):639-651.
52. Zai C.C., Tiwari A.K., De Luca V., Müller D.J., Bulgin N., Hwang R., Zai G.C., King N., Voineskos A.N., Meltzer H.Y., Lieberman J.A., Potkin S.G., Remington G., Kennedy J.L. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur. Neuropsychopharmacol. 2009, 19(5):317-328.
53. Zai C.C., Tiwari A.K., Basile V., de Luca V., Müller D.J., Voineskos A.N., Remington G., Meltzer H.Y., Lieberman J.A., Potkin S.G., Kennedy J.L. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(1):50-56.
54. Zai C.C., Tiwari A.K., Müller D.J., De Luca V., Shinkai T., Shaikh S., Ni X., Sibony D., Voineskos A.N., Meltzer H.Y., Lieberman J.A., Potkin S.G., Remington G., Kennedy J.L. The catechol-O-methyl-transferase gene in tardive dyskinesia. World J. Biol. Psychiatry 2010, 11(6):803-812.
55. Zhang X.Y., Zhang W.F., Zhou D.F., Chen, da C., Xiu M.H., Wu H.R., Haile C.N., Kosten T.A., Kosten T.R. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol. Psychiatry 2012, 72(8):700-706.
56. Zhang J.P., Lencz T., Geisler S., DeRosse P., Bromet E.J., Malhotra A.K. Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophr. Res. 2013, 146(1-3):285-288.